Recombinant human erythropoietin for injection (CHO cells)

Erythropoietin is an active glycoprotein secreted by the kidneys. It acts on erythroid hematopoietic progenitor cells in the bone marrow and promotes their proliferation and differentiation. This product can induce a significant effect of stimulating colony formation through late-stage mother erythroid progenitor cells (CFUE). At high concentrations, this product can also stimulate early-stage mother erythroid progenitor cells (BFUE) to induce colony formation.

Recombinant human erythropoietin

White freeze-dried powder injection

Anemia caused by renal insufficiency, including patients with chronic renal failure undergoing hemodialysis, peritoneal dialysis and non-dialysis patients.

This product should be used under the guidance of a doctor. When used, add 1 ml of injection water to dissolve it and then inject it subcutaneously or intravenously. It should be administered 2 to 3 times a week. The dosage should be adjusted according to the patient's anemia degree, age and other relevant factors. Treatment period: The recommended dosage for hemodialysis patients is 100 to 150 IU/kg per week, and for peritoneal dialysis and non-dialysis patients is 75 to 100 IU/kg per week. If the hematocrit increases by less than 0.5 vol% per week, the dose can be increased by 15 to 30 IU/kg after 4 weeks, but the maximum increase should not exceed 30 IU/kg/week. The hematocrit should increase to 30 to 33 vol%, but should not exceed 36 vol% (34 vol%). Maintenance period: If the hematocrit reaches 30 to 33 vol% or/and the hemoglobin reaches 100 to 110 g/L, the maintenance treatment stage will be entered. It is recommended to adjust the dose to 2/3 of the therapeutic dose and then check the hematocrit every 2 to 4 weeks to adjust the dose, avoid excessive erythrocyte production, and maintain the hematocrit and hemoglobin at appropriate levels.

1. General reactions: A few patients may experience headache, low fever, fatigue, etc. at the beginning of medication, and some patients may experience myalgia, joint pain, etc. Most adverse reactions can be improved after symptomatic treatment and will not affect continued medication. In very few cases, the above symptoms persist and medication should be discontinued. 2. Allergic reactions: A very small number of patients may experience allergic reactions such as rash or urticaria after medication, including anaphylactic shock. Therefore, when using this product for the first time or reusing this product, it is recommended to use a small amount first, and then inject the full amount after confirming that there is no abnormal reaction. If abnormalities are found, the drug should be discontinued immediately and properly handled. 3. Cardiovascular and cerebrovascular system: increased blood pressure, worsening of existing hypertension, headache, impaired consciousness, spasm due to hypertensive encephalopathy, and even cerebral hemorrhage. Therefore, during the treatment of erythropoietin injection, attention should be paid to and regular observation of blood pressure changes. If necessary, the dose should be reduced or discontinued, and the dose of antihypertensive drugs should be adjusted. 4. Blood system: With the increase of hematocrit, blood viscosity can increase significantly, so care should be taken to prevent thrombosis. 5. Liver: Occasionally, GOT and GPT may increase. 6. Gastrointestinal: Sometimes, nausea, vomiting, loss of appetite, diarrhea, etc. may occur.

1. Patients with uncontrolled severe hypertension. 2. Patients who are allergic to this product or other erythropoietin preparations. 3. Patients with concurrent infections should use this product only after the infection is controlled.

Precautions for children: The safety of the drug for premature infants, newborns, and infants has not yet been established. Precautions for pregnancy and lactation: It is still unknown. Precautions for the elderly: When elderly patients use this product, they should pay attention to monitoring blood pressure and hematocrit, and adjust the dosage and frequency of medication appropriately.

Not yet clear.

Store at 2～8℃ away from light

3000IU/bottle

24 months

Chengdu DIAO Jiuhong Pharmaceutical Factory

• Founded in:

  1996-11-27

• Address:

  No. 16, Gaopeng East Road, Chengdu Hi-tech Zone

• Tax NO.:

  91510100202172097P

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view